Trial Profile

A Phase 1b/2a, Open-Label Study to Evaluate the Safety, Tolerability and Immunogenicity of VTP-300 With or Without Nivolumab in Participants With Chronic Hepatitis B Infection

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VTP 300 (Primary) ; Antivirals; MVA HBV; Nivolumab; Programmed cell death 1 receptor modulators
Indications Hepatitis B
Focus Adverse reactions; First in man
Sponsors Barinthus Biotherapeutics

Most Recent Events

13 Aug 2024 Status changed from active, no longer recruiting to completed.
24 Jun 2023 Results assessing the effect of ChAdOx1-HBV/MVA-HBV immunotherapy (VTP-300) combined with low-dose nivolumab (LDN) in virally suppressed patients with CHB presented at the European Association for the Study of the Liver Congress 2023
21 Jun 2023 Positive final results presented in the Vaccitech Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com